Drug Profile
Plague vaccine injectable - DynPort/USAMRIID
Alternative Names: Recombinant F1V plague vaccine - Dynport Vaccine Company; rF1V vaccineLatest Information Update: 23 Aug 2022
Price :
$50
*
At a glance
- Originator United States Army Medical Research Institute of Infectious Diseases
- Developer DynPort Vaccine Company
- Class Plague vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Yersinia infections
Most Recent Events
- 23 Aug 2022 Dynavax Technologies Corporation initiates enrolment in a phase II trial for Yersinia infections in USA (NCT05506969)
- 17 Mar 2017 Plague vaccine injectable is still in phase II trials for prevention of Yersinia infections in USA
- 08 Mar 2017 Plague vaccine injectable - DynPort/USAMRIID receives Orphan Drug status for Yersinia infections in USA